# Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia

> **NCT00065260** · PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 54 (actual)

## Conditions studied

- Aplastic Anemia

## Interventions

- **DRUG:** Campath-1H
- **DRUG:** r-ATG
- **DRUG:** CsA

## Key facts

- **NCT ID:** NCT00065260
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11-06
- **Primary completion:** 2010-12-29
- **Final completion:** 2016-02-05
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2021-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00065260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00065260, "Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00065260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*